Karyopharm Therapeutics Inc. (KPTIQ)
| Market Cap | 576.11K -99.4% |
| Revenue (ttm) | 146.62M +6.8% |
| Net Income | -224.74M |
| EPS | -11.58 |
| Shares Out | 22.68M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,499,539 |
| Open | 0.0275 |
| Previous Close | 0.0255 |
| Day's Range | 0.0210 - 0.0290 |
| 52-Week Range | 0.0080 - 10.9900 |
| Beta | 1.21 |
| Analysts | Buy |
| Price Target | 7.00 (+27,459.06%) |
| Earnings Date | n/a |
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compounds include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myelom... [Read more]
Financial Performance
In 2025, Karyopharm Therapeutics's revenue was $146.07 million, an increase of 0.57% compared to the previous year's $145.24 million. Losses were -$196.04 million, 156.5% more than in 2024.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for KPTIQ stock is "Buy." The 12-month stock price target is $7.00, which is an increase of 27,459.06% from the latest price.
News
Karyopharm to Present Selinexor Data in Patients with Myelofibrosis and Multiple Myeloma at the 68th American Society of Hematology Annual Meeting and Exposition (ASH)
– Week 48 Data from the Phase 3 SENTRY Trial Selected for Oral Presentation – – Data from the Phase 2 SENTRY-2 Trial Selected for Oral Presentation – NEWTON, Mass., Nov. 4, 2026 /PRNewswire/ -- Karyop...
Karyopharm Therapeutics Inc. Announces Planned Merger with Ayrmid Ltd. to Strengthen Company for the Future
– The Company Remains Focused on Supporting Patients and Advancing its Programs in Multiple Myeloma and Myelofibrosis – – Ayrmid will Serve as Lead Bidder in Court-Supervised Sale Process to Maximize ...
Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NEWTON, Mass., Oct. 1, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company g...
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWTON, Mass., Sept. 1, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company ...
Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO® (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis
– sNDA Submitted under the Accelerated Approval Pathway; Priority Review Requested – NEWTON, Mass., Aug. 31, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharma...
Karyopharm Therapeutics Earnings Call Transcript: Q2 2026
Selinexor advanced toward sNDA submission for myelofibrosis, supported by strong phase III data and constructive FDA engagement. Q2 revenue was $33.4M, with stable XPOVIO sales and disciplined expense management. Liquidity risks remain, but financing options are being pursued.
Karyopharm Therapeutics Earnings release: Q2 2026
Karyopharm Therapeutics released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
Karyopharm Therapeutics Quarterly report: Q2 2026
Karyopharm Therapeutics has published its Q2 2026 quarterly earnings report on August 13, 2026.
Karyopharm Therapeutics Slides: Q2 2026
Karyopharm Therapeutics has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 13, 2026.
Karyopharm Reports Second Quarter 2026 Financial Results and Highlights Continued Progress Toward Myelofibrosis sNDA Submission
– Planned August sNDA Submission for Selinexor in Combination with Ruxolitinib in Myelofibrosis under the Accelerated Approval Pathway Remains on Track – – Planned sNDA for Selinexor plus Ruxolitinib ...
Karyopharm to Report Second Quarter 2026 Financial Results on August 13, 2026
-- Conference Call Scheduled for Thursday, August 13, 2026, at 8:00 a.m. ET -- NEWTON, Mass.
Karyopharm Plans to Submit sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis Under Accelerated Approval Pathway
– Company Plans to Submit sNDA in August 2026 and Will Request Priority Review – – Following FDA Engagements, Company Plans to Submit sNDA under Accelerated Approval Based Upon Compelling SVR35 Data a...
Karyopharm Announces Topline Results from Phase 3 XPORT-EC-042 Trial in Endometrial Cancer
– The Trial Did Not Meet the Primary Endpoint of Progression-Free Survival (PFS) – – A Trend Favoring the Selinexor Arm was Observed with a 5.3 Month Improvement in Median PFS Relative to the Placebo ...
Karyopharm Therapeutics Transcript: Jefferies Global Healthcare Conference 2026
Significant progress reported in myelofibrosis and endometrial cancer programs, with phase III SENTRY data showing strong efficacy and survival signals in myelofibrosis and EC-042 readout expected mid-year. Regulatory and commercial strategies are in place, with cash runway into late Q3.
Karyopharm Therapeutics Slides: Investor presentation
Karyopharm Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on June 4, 2026.
Karyopharm to Participate in Webcast Featuring Endometrial Cancer Key Opinion Leader on June 8, 2026
NEWTON, Mass., June 3, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it will parti...
Karyopharm Therapeutics Transcript: Study result
The phase III SENTRY trial showed selinexor plus ruxolitinib significantly improved spleen volume reduction and provided an early survival benefit in JAK inhibitor-naive myelofibrosis patients, with manageable safety and consistent efficacy across subgroups. SVR35 correlated with survival, and the combination may address real-world dosing challenges.
Karyopharm Therapeutics Press release: Study result
Karyopharm Therapeutics issued a press release on June 2, 2026, disclosing material business information to investors.
Karyopharm Therapeutics Slides: Study result
Karyopharm Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on June 2, 2026.
Karyopharm's Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-Breaking Oral Presentation at EHA 2026
– New Data will Highlight a Post-Hoc Analysis from Phase 1 Portion of SENTRY Trial that Indicates Achievement of SVR35 with Selinexor plus Ruxolitinib May Predict Overall Survival – – Selected by EHA'...
Karyopharm to Present Results from Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis in Late-Breaking Oral Presentation at ASCO 2026 with Simultaneous Publication in the Journal of Clinical Oncology
– Selinexor in Combination with Ruxolitinib Demonstrated a Rapid and Near Doubling of Patients Achieving SVR35 at Week 24, versus Ruxolitinib, with a Consistent SVR35 Benefit Observed Across Prespecif...
Karyopharm to Host Investor Conference Call Featuring Expert Perspectives on the Phase 3 SENTRY Trial in Myelofibrosis Following 2026 ASCO Presentation
– Event To Feature Dr. John Mascarenhas, Principal Investigator of the Phase 3 SENTRY Trial – – Conference Call Scheduled for Tuesday, June 2, 2026 at 2:00 p.m. ET – NEWTON, Mass.
Karyopharm to Participate at the 2026 Jefferies Global Healthcare Conference
NEWTON, Mass., May 28, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's...
Karyopharm Therapeutics Transcript: AGM 2026
The meeting confirmed a quorum and approved all five proposals, including director elections, plan amendments, executive compensation, and auditor ratification. No questions were raised by shareholders, and final voting results will be filed in a Form 8-K.
Karyopharm Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2026
Phase III SENTRY data for selinexor plus ruxolitinib in myelofibrosis show rapid, deep responses and a strong early survival signal, with full results to be presented at ASCO. Regulatory and guideline engagement is progressing, and the endometrial cancer program targets a high unmet need subgroup.